02-0 89, P = 0 018) We concluded that p53 arg/pro polymorphism h

02-0.89, P = 0.018). We concluded that p53 arg/pro polymorphism has different pattern of frequency in different types of cancer among Sudanese patients, indicating perhaps different etiology and biology of these tumours.”
“Objective: We analyzed autoantibodies against tumor-associated antigens (TAAs) in the

serum of patients with endometrioma and healthy controls to determine whether autoantibodies can be accurate biomarkers for the diagnosis of ovarian endometrioma. Methods: Serum samples were obtained from 56 patients with endometriosis and 66 healthy women who served as normal controls. The titers of antibodies against a panel of eight TAAs were analyzed using CHIR-99021 price enzyme-linked immunosorbent assay. Results: We found that the serum IGFII mRNA-binding protein 1 (IMP1) autoantibody and cyclin B1 autoantibody could discriminate between healthy controls and endometriosis patients (AUC-ROC 0.777; 95% confidence interval [CI] 0.694-0.860, P < 0.0005, and AUC-ROC 0.614; 95% confidence interval [CI] 0.513-0.714, P = 0.031, respectively). Using 0.073 and 0.007 as the cutoff values for Selleckchem Adriamycin IMP1 and Cyclin B1 autoantibody, respectively, the sensitivity and specificity of IMP1 were 85.7 and 63.6%, respectively. When cylcin B1 was combined with IMP1, the specificity increased to 72.7% and the sensitivity slightly decreased to 83.9%. Conclusions: Our data suggest that IMP1 alone or

combined with cyclin B1 seems to fulfill the requirements of sensitivity and specificity to become a useful clinical biomarker of endometrioma. However, further studies will be required to establish the predictive value and to support the clinical use of IMP1/cyclin Fosbretabulin chemical structure B1 in the diagnosis and/or screening of endometriosis. J. Clin. Lab. Anal. 24:357-362, 2010. (C) 2010 Wiley-Liss, Inc.”
“BACKGROUND: The mechanisms

and management of delayed intracerebral hemorrhage (dICH) after treatment of brain arteriovenous malformations (AVMs) are poorly understood and widely debated. Many clinical predictive factors have been theorized for dICH after an otherwise uneventful AVM embolization, but there is an absence of data to discern their significance.\n\nOBJECTIVE: To analyze 13 proposed predictive factors and to assess their potential in guiding prevention strategies.\n\nMETHODS: One hundred sixty-eight embolization procedures were performed on 67 patients with brain AVMs by a single surgeon. Patients were divided into 2 groups: those with symptomatic dICH and control subjects. Thirteen factors were analyzed: age, sex, race, previous ICH, Spetzler-Martin grade, AVM size, eloquence, embolic volume, embolic agent, percent obliteration, and timing, number, and stage of embolizations. Univariate and multivariate analyses were performed on these factors to determine significance.\n\nRESULTS: Six procedures were complicated by dICH; 5 (83%) occurred after the final planned procedure. The volume of embolic agent was significantly higher in the dICH group (4.5 +/- 1.

Comments are closed.